We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.36% | 45.14 | 45.15 | 44.945 | 45.06 | 641,180 | 18:01:58 |
From May 2019 to May 2024
By Denise Roland
Vaccines giant GlaxoSmithKline PLC said Monday it would donate a vaccine-booster to groups racing to develop a shot against the new coronavirus.
Glaxo has developed a so-called adjuvant, which it uses in its seasonal flu shot, that can make a vaccine more effective, meaning that smaller doses are needed to achieve immunity.
Glaxo is working with the Coalition for Epidemic Preparedness Innovations, the Norwegian nonprofit that is funding several of the groups trying to develop a new vaccine.
One of those groups, the University of Queensland, said it will use the Glaxo adjuvant as it develops its candidate vaccine.
CEPI Chief Executive Richard Hatchett said Glaxo's contribution has the potential to make more vaccine available more rapidly, by making a given supply of vaccine go farther and increasing the number of people who can benefit.
(END) Dow Jones Newswires
February 02, 2020 19:26 ET (00:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
